Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 72 points (-0.4%) at 17,208 as of Monday, Sept. 22, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 456 issues advancing vs. 2,548 declining with 145 unchanged. The Drugs industry currently sits down 2.1% versus the S&P 500, which is down 0.8%. On the negative front, top decliners within the industry include Intercept Pharmaceuticals ( ICPT), down 5.0%, Incyte ( INCY), down 4.3%, Illumina ( ILMN), down 2.5%, Grifols ( GRFS), down 2.2% and Alexion Pharmaceuticals ( ALXN), down 2.0%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. AbbVie ( ABBV) is one of the companies pushing the Drugs industry lower today. As of noon trading, AbbVie is down $0.54 (-0.9%) to $58.52 on average volume. Thus far, 4.5 million shares of AbbVie exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $58.42-$59.30 after having opened the day at $59.29 as compared to the previous trading day's close of $59.06. AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $94.6 billion and is part of the health care sector. Shares are up 11.8% year-to-date as of the close of trading on Friday. Currently there are 5 analysts that rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.